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Adolescent immunisation: the next 
big thing?
Adam Finn,1 Ed Clarke,1 Julie Mytton2
step would see the addition of acellular 
pertussis to the Td/IPV adolescent vac-
cine. Indeed, adolescent pertussis vac-
cination has already been instituted in 
a number of countries including France, 
Germany and the USA following its rec-
ommendation by the Global Pertussis 
Initiative.9 10 Currently, severe and fatal 
cases of pertussis continue to occur in 
infants too young to have been fully 
immunised. Epidemiological studies 
suggest that this is because Bordetella per-
tussis continues to circulate, particularly 
in young adults whose vaccine-induced 
immunity has worn off, causing per-
sistent coughs and, on rare but devas-
tating occasions, transmission to their 
recently born offspring or other infant 
contacts.11
Notwithstanding the eventual tri-
umph, in the UK in 1988, of universal 
rubella immunisation over selective 
immunisation of young adolescent girls, 
cost-benefi t calculations have effectively 
ruled out offering HPV vaccine to ado-
lescent boys, at least for the present12 and 
have also resulted in UK use of bivalent 
rather than quadrivalent HPV vaccine. 
However, such considerations might not 
apply to immunisation against the other 
vaccine-preventable, sexually transmit-
ted, cancer-causing virus—hepatitis B, 
as the vaccine is much cheaper. In 1992, 
the WHO recommended universal hepa-
titis B immunisation in all countries, giv-
ing the option of adolescent, rather than 
infant immunisation in low prevalence 
countries, such as the UK.13 Discussions 
about the implementation of universal 
hepatitis B immunisation in the UK are 
on-going and could eventually culminate 
in inclusion of the vaccine into the infant 
schedule if the logistics and cost can be 
got right. An alternative for the UK could 
be the immunisation of young teenagers, 
close to the age of onset of sexual activity. 
The communication issues are similar to 
those relating to HPV—in the end the only 
major difference from the recipient’s per-
spective is that the cancer to be prevented 
is in a different organ. Furthermore, the 
three dose schedules match and it is 
already known that the vaccines can be 
given concomitantly without loss of the 
protective effi cacy of either.14
Meningococcal disease in the UK pri-
marily affects infants and young children, 
with a second smaller peak occurring in 
adolescents.15 The overall incidence rates 
and relative predominance of different 
meningococcal serogroups varies widely 
between continents and regions and this 
has infl uenced how vaccines have been 
Although not without problems,1 the 
programme has been very successful to 
date, with uptake rates of between 80% 
and 90%.2 Furthermore, despite concerns 
to the contrary, a workable and effective 
means of involving both parents and 
children in the consent process has been 
implemented.3–5 Inevitably, disorders 
developing during the days, weeks and 
months after immunisation will con-
tinue to be attributed to the vaccine by 
some, despite the availability of valuable 
baseline epidemiology against which 
incidence rates can be benchmarked.6 7 
But, with luck, both the public and the 
media will have learnt enough following 
the false alarmism surrounding measles 
mumps rubella (MMR) and autism, to 
know that chronology does not always 
denote causality. On the back of this 
success, is there scope to widen this 
approach to include other vaccines for 
which a case can be made for universal 
administration, to young teenagers and, 
in association with this, is there a case 
for offering HPV immunisation to boys 
as well as girls?
It is not hard to fi nd additional candi-
dates. A booster vaccine combining teta-
nus, low dose diphtheria and trivalent 
inactivated polio (Td/IPV) is already rec-
ommended for teenagers aged between 
13 and 18 years of age within the stan-
dard schedule. However, reported 
uptake rates of Td/IPV are highly vari-
able between primary care trusts (PCTs) 
due to differences in the Child Health 
reporting systems. Some areas are 
unable to report any data, while oth-
ers under-report due to incomplete age 
groups or incomplete identifi cation of 
children eligible to receive the boost-
er.8 Transferring this programme to run 
alongside HPV for girls, and as a plat-
form upon which to build a secondary 
school-based programme for boys would 
require standardisation of collection sys-
tems for the Td/IPV booster and should 
lead to complete and accurate recording 
of uptake rates. Ensuring that more indi-
viduals receive a fi fth dose of these anti-
gens is important as they are thought to 
be required to ensure reliable individual 
protection into adult life. A small further 
INTRODUCTION
The recent introduction of the human 
papillomavirus (HPV) vaccine into the 
routine immunisation schedule for girls 
in the UK has reaffi rmed the possibility 
of widespread adolescent immunisation, 
assuming appropriate prior consultation 
and resource allocation. On the back of 
this success, it is timely to consider the 
case for extending the programme of 
school-based adolescent immunisations 
to include the provision of both addi-
tional primary immunisations as well 
as important booster doses of vaccines 
given earlier in childhood. Such a pro-
gramme, if well designed, would ensure 
that individual protection from vaccine 
preventable disease was maximised prior 
to school leaving and, of equal impor-
tance in some cases, that herd immu-
nity was sustained more effectively in 
the population as a whole. The possible 
contents of a re-invigorated adolescent 
immunisation programme are discussed 
considering those vaccines which are 
already available and for which cost-ben-
efi t calculation may therefore be of prime 
importance, as well as vaccines which 
may become available in the future and 
for which the issues may be more com-
plicated. The importance of provid-
ing balanced, accurate, appropriate and 
accessible information regarding adoles-
cent immunisation is also highlighted.
INTRODUCTION OF THE HPV 
VACCINATION PROGRAMME
The introduction of routine human 
papillomavirus (HPV) vaccination for 
12-year-old girls in 2008 represented a 
return to a public health strategy which 
had been abandoned in the UK with 
the discontinuation of routine BCG: 
namely the use of a rolling school-based 
adolescent immunisation programme. 
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immunisations so that missed vaccine 
doses can be given at school-based ses-
sions, maximising individual and herd 
protection. This could reduce the recent 
regular outbreaks of mumps in univer-
sity students, some of which have been 
widespread.35 Such a facility could mean 
that, over time, the requirement for occa-
sional catch-up programmes, as required 
in recent times with measles,36 which are 
both expensive and logistically diffi cult 
to organise over and above more regu-
lar workloads, could be avoided. School 
Nursing Teams have been stretched to 
deliver the current HPV catch up pro-
gramme as well as their pre-existing 
commitments, so the establishment of a 
routine school based adolescent immu-
nisation programme would require care-
ful workforce planning. The ability to 
expand workforces would be challenging 
in the current fi nancial climate. Finally 
the existence of a well- established school 
programme would provide an infrastruc-
ture upon which occasional unscheduled 
requirements, such as the delivery of 
pandemic fl u vaccines, could much more 
easily be added.
The provision of immunisation to 
teenagers needs to be done with some 
consideration. Reports of epidemics of 
needle-phobia-related fainting among 
girls queuing for HPV vaccine provide 
examples of suboptimal organisation.6 
Conversely some of the information 
developed to provide information about 
the vaccine to this target group in the 
UK appears to have been well designed 
and well received. The future success 
of immunisation at all ages depends 
critically upon the effective provision of 
accurate, balanced, understandable, and 
when asked for, detailed information 
both about particular vaccines and about 
immunisation in general instead of the 
standard diet of scare stories. Nowhere 
will this be more pertinent than among 
adolescents.
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awakenings are normally driven by a 
severe or fatal case of chickenpox, but 
on this occasion the trigger was a posi-
tive opinion from the Joint Committee 
on Vaccination and Immunisation con-
cerning zoster vaccine for older people.27 
Alongside cost-benefi t calculations, 
a hypothetical temporary increase in 
zoster rates consequent upon disappear-
ance of varicella cases among children 
and thus, in principle, a reduction in the 
boosting of cell mediated immunity in 
their adult contacts, is frequently cited as 
a bar to universal childhood immunisa-
tion.28 29 In reality, reluctance to desta-
bilise the recovery of the thoroughly 
disrupted MMR programme by adding 
varicella either alongside it or combined 
as MMRV may be at least as important. 
While such deliberations play themselves 
out, an opportunity exists, within a 
reinvigorated adolescent programme, to 
immunise adolescents with no history of 
chickenpox, as has been advocated in the 
USA.30 Adults who get varicella are more 
likely to get seriously ill than children, so 
that protecting the one in 20 or so who 
escape the infection in childhood makes 
good sense. The rash is easily recognised 
so a positive history is fairly specifi c.31 
While many individuals with a negative 
history will nonetheless be immune,31 
unnecessary vaccination will do no 
harm and could be done easily within an 
established school based immunisation 
programme for all teenagers whereas 
the cost and logistics of doing serological 
screening prior to vaccination make this 
unlikely to be workable.
What other developments could occur 
in adolescent immunisation in the fore-
seeable future? A broader range of vac-
cines against sexually transmitted 
infections (STIs) may become available. 
As occurred with HPV vaccine, there will 
be some who argue against progressing in 
this direction on moral grounds, propos-
ing that it will remove an inhibition to 
initiation of sexual behaviour. Whether 
or not the prevailing consensus endorses 
such views, vaccines against STIs includ-
ing herpes simplex virus type 2 and chla-
mydia are likely to become available in 
the future32–34 and this will raise ques-
tions about whether and how to deploy 
them.
More generally, PCTs might choose to 
use the well-established and robust Child 
Health systems containing the immuni-
sation status of preschool children resi-
dent in their patch, to permit clinical staff 
running school programmes to ascertain 
precise details of each child’s previous 
developed and used. Effective conjugated 
capsular polysaccharide vaccines are now 
licensed and available in Europe against 
disease caused by serogroups A, C, Y and 
W135. In contrast, vaccines against sero-
group B strains (Men B) have been much 
harder to develop although they have 
been used to control epidemic disease, 
caused by single strains in Cuba and New 
Zealand.16–18 Furthermore, at least one 
vaccine with predicted effi cacy against a 
proportion of endemic Men B disease is 
in clinical trials in the UK.17 19 Disease 
caused by Men C, a serogroup previously 
prevalent in the UK, has dramatically 
reduced following introduction of uni-
versal Men C conjugate vaccination in 
1999–2000.20 However, the introduction 
included a large catch-up programme in 
children and young adults then aged up 
to 23 years. The greater population cov-
erage, with associated herd immunity, 
afforded by the catch-up programme is 
progressively disappearing as the immu-
nised cohort gets older and is replaced by 
children who have only been immunised 
in infancy or, since 2006, infancy and 
the second year of life. Recent evidence 
indicates that antibody levels in children 
such as this, immunised in early life, 
fall away towards baseline by the age 
of between 2 and 3 years.21 Accordingly 
we may be heading towards a situation 
where Men C disease starts to return,22 
somewhat like the re-emergence of Hib 
disease early in the fi rst decade of this 
century.23 The logical solution is prob-
ably, once again, adolescent booster 
immunisation—an approach given 
further impetus by the fact that cur-
rently available evidence suggests that 
immune responses may be signifi cantly 
longer-lasting if the vaccines are given 
in the second decade of life than if they 
are given early in the fi rst.24 Adolescent 
booster immunisation could therefore 
serve, not only to generate long lasting 
protection for the individual, but also to 
sustain herd immunity in the population 
as a whole. Such boosting could be with 
conjugate Men C vaccine or, given that 
small numbers of cases of Men A, Y and 
W135 disease do occur, with quadrivalent 
vaccine instead, assuming the cost-bene-
fi t calculations could be made to work.25 
26 Similar arguments may apply to Men 
B vaccines if and when vaccines with the 
necessary breadth of coverage in the UK 
become available and if they are shown 
to reduce incidence of carriage.
Media interest in the fact that immu-
nisation against varicella is not routine 
in the UK was rekindled recently. Such 
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